Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-12 · 46 (12)
DOI: 10.1002/phar.70220 ↗Kurz gefasst
Scoping Review in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 18.11.2026. Verfasst von Amina Ammar und 5 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben.
Abstract (Originalsprache)
Patients receiving therapeutic oral anticoagulation (OAC) often have indications for antiplatelet therapy. Historically, antiplatelet agents have been used alongside therapeutic anticoagulation, increasing the risk of bleeding without a proven reduction in thrombosis. This scoping review summarizes recent evidence evaluating OAC monotherapy compared with combination therapy consisting of OAC plus antiplatelet agent among patients with atrial fibrillation and stable coronary artery disease, cerebrovascular disease, and prosthetic heart valves. We searched PubMed, Embase, CENTRAL, and International Pharmaceutical Abstracts to identify randomized controlled trials (RCTs) evaluating these strategies. Included studies enrolled adults receiving therapeutic anticoagulation across different cardiovascular disease states that reported efficacy and safety outcomes. Two reviewers independently screened studies and extracted data, with disagreements resolved by a third reviewer. Published subgroup analyses of included RCTs were also reviewed. After screening 10,008 records, 11 RCTs met inclusion criteria. Evidence supporting OAC monotherapy was observed in patients with atrial fibrillation and stable coronary artery disease; OAC monotherapy consistently reduced bleeding without increasing ischemic events compared with combination therapy. Similar reductions in bleeding were observed in patients with cerebrovascular disease, although evidence remains limited by small sample size and early trial termination. Among patients undergoing transcatheter aortic valve replacement with an indication for chronic anticoagulation, OAC monotherapy reduced bleeding without compromising ischemic outcomes. Evidence supporting discontinuation of antiplatelet therapy in patients with mechanical heart valves remains limited. Additional RCTs are needed to better define the role of antiplatelet therapy in cerebrovascular disease, prosthetic heart valves, and other high‐risk populations.
Zitieren
APA
Ammar, A., Edwin, S. B., Reed, J. B., Kaatz, S., Barnes, G. D., & Giuliano, C. (2026). Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(12). https://doi.org/10.1002/phar.70220
Vancouver
Ammar A, Edwin SB, Reed JB, Kaatz S, Barnes GD, Giuliano C. Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(12). doi:10.1002/phar.70220
BibTeX
@article{Ammar2026,
author = {Ammar, Amina and Edwin, Stephanie B. and Reed, Jason B. and Kaatz, Scott and Barnes, Geoffrey D. and Giuliano, Christopher},
title = {Antiplatelet Use in the Setting of Therapeutic Anticoagulation: A Scoping Review},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {12},
doi = {10.1002/phar.70220}
}
EUVIMED